Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.
In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future.
Some of the most widely used drug contractors are based in China. But the U.S. biopharmaceutical industry may eventually be pushed to cut ties with those partners if the Biosecure Act, which passed in ...
TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), proudly announces the launch of its new mission statement and tagline: Empowering Partners. Enriching Lives. This ...
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.
It’s a real opportunity to reinforce hope and to start getting comfortable with the word ‘cure,” said a leader of the study, which tested Opdivo and Yervoy.